Solid Biosciences Inc. Impairment of Long-Lived Assets Held-for-use
Solid Biosciences Inc. (SLDB) reported Impairment of Long-Lived Assets Held-for-use of $0 for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfLongLivedAssetsHeldForUse · last filed 2025-03-06
- Solid Biosciences Inc. impairment of long-lived assets held-for-use for the quarter ending 2024-03-31 was $0.00, a 100.00% decline year-over-year.
- Solid Biosciences Inc. impairment of long-lived assets held-for-use for the quarter ending 2023-12-31 was $26.00K.
- Solid Biosciences Inc. impairment of long-lived assets held-for-use for the quarter ending 2023-09-30 was $0.00.
- Solid Biosciences Inc. impairment of long-lived assets held-for-use for the quarter ending 2023-06-30 was $0.00.
- Solid Biosciences Inc. impairment of long-lived assets held-for-use for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- Solid Biosciences Inc. impairment of long-lived assets held-for-use for fiscal 2023 was $400.00K.
- Solid Biosciences Inc. impairment of long-lived assets held-for-use for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
- Solid Biosciences Inc. impairment of long-lived assets held-for-use for fiscal 2021 was $92.00K.
| Period end | Impairment of Long-Lived Assets Held-for-use 3 month | Impairment of Long-Lived Assets Held-for-use 3 month as first filed | Impairment of Long-Lived Assets Held-for-use 6 month | Impairment of Long-Lived Assets Held-for-use 9 month | Impairment of Long-Lived Assets Held-for-use 12 month | Impairment of Long-Lived Assets Held-for-use 12 month as first filed |
|---|---|---|---|---|---|---|
| 2024-12-31 | $0.00 10-K · filed 2025-03-06 | |||||
| 2024-03-31 | $0.00 10-Q · filed 2024-05-15 | $26.00K derived: sum of 2 quarters · filed 2025-03-06 | $26.00K derived: sum of 3 quarters · filed 2025-03-06 | $26.00K derived: sum of 4 quarters · filed 2025-03-06 | ||
| 2023-12-31 | $26.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $26.00K derived: sum of 2 quarters · filed 2025-03-06 | $26.00K derived: sum of 3 quarters · filed 2025-03-06 | $400.00K 10-K · filed 2025-03-06 | $374.00K 10-K · filed 2024-03-13 | |
| 2023-09-30 | $0.00 10-Q · filed 2023-11-08 | $0.00 derived: sum of 2 quarters · filed 2023-11-08 | $374.00K 10-Q · filed 2023-11-08 | $400.00K derived: sum of 4 quarters · filed 2024-05-15 | ||
| 2023-06-30 | $0.00 10-Q · filed 2023-08-14 | $374.00K 10-Q · filed 2023-08-14 | $400.00K derived: sum of 3 quarters · filed 2024-05-15 | $400.00K derived: sum of 4 quarters · filed 2024-05-15 | ||
| 2023-03-31 | $400.00K 10-Q · filed 2024-05-15 | $374.00K 10-Q · filed 2023-05-11 | $400.00K derived: sum of 2 quarters · filed 2024-05-15 | $400.00K derived: sum of 3 quarters · filed 2024-05-15 | $400.00K derived: sum of 4 quarters · filed 2024-05-15 | |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | $0.00 derived: sum of 2 quarters · filed 2024-03-13 | $0.00 derived: sum of 3 quarters · filed 2024-03-13 | $0.00 10-K · filed 2024-03-13 | ||
| 2022-09-30 | $0.00 10-Q · filed 2023-11-08 | $0.00 derived: sum of 2 quarters · filed 2023-11-08 | $0.00 10-Q · filed 2023-11-08 | |||
| 2022-06-30 | $0.00 10-Q · filed 2023-08-14 | $0.00 10-Q · filed 2023-08-14 | ||||
| 2022-03-31 | $0.00 10-Q · filed 2023-05-11 | |||||
| 2021-12-31 | $92.00K 10-K · filed 2024-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |